OncoMatch/Clinical Trials/NCT04996823
Axitinib + Ipilimumab in Advanced Melanoma
Is NCT04996823 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ipilimumab and Axitinib for melanoma.
Treatment: Ipilimumab · Axitinib — The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Allowed: BRAF V600
If BRAFV600-mutant melanoma, patients may have had prior BRAF/MEK inhibitor therapy, or intolerance to these drugs
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy — metastatic or adjuvant (if relapse on or within 6 months from end of anti-PD-1 treatment)
Documented disease refractory or intolerant to anti-PD-1/PD-L1 inhibitor treatment: in the metastatic setting or in the adjuvant setting if relapse on or within 6 months from end of anti-PD-1 treatment
Cannot have received: CTLA-4 inhibitor (ipilimumab)
prior ipilimumab not permitted
Lab requirements
Blood counts
Adequate bone marrow as defined in protocol
Kidney function
Adequate organ function as defined in protocol
Liver function
Adequate organ function as defined in protocol; in patients with known liver cirrhosis, those with severe (Child Pugh C) hepatic impairment are excluded.
Adequate bone marrow, organ function and laboratory parameters as defined in protocol. In patients with known liver cirrhosis, those with severe (Child Pugh C) hepatic impairment are excluded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify